Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Search by Keyword
Sort By
  • Fundamentals of Liver Disease- Hepatitis B

    Contains 16 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    The Fundamentals of Liver Disease Hepatitis B unit currently does not offer CME, CE or MOC. This unit is available for viewing purposes only. A newly updated version will be available soon for credits or points. Check back for updates!

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.


    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    HBV: Epidemiology and Screening
    Patient with positive Hepatitis B serologies
    Natural history of HBV and identification of treatment candidates
    Management of the Chronic HBV patient with co-morbid and other conditions
    Antiviral treatment of the Patient with Chronic HBV
    Prevention of HBV infection
    Hepatitis B in the Pediatric Patient

    7 online interactive, narrated modules 30 to 40 minutes in length
    Pre- and post-test questions for each module

    Original release date: April 10, 2014
    Review date: July 1, 2017
    Re-release date: December 1, 2017
    Expiration date: November 30, 2019
    Time to complete each module: 45-60 minutes

    All faculty in this activity have given their permission for publication OR
    ©2017 AASLD

    Contact Information
    For questions on CE credit for this activity contact
    For questions on MOC/CME/CE content or the activity web site, contact

    Marc G. Ghany

    Dr. Ghany is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 


    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.



    Marion G. Peters

    Anna S. Lok

    Brian J. McMahon

    Maureen M. Jonas

    Learning Objective:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.


    Accreditation Statement

    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Credit Designation

    AASLD designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Amedco is accredited as a provider of continuin nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and AASLD. Maximum of 3.5 contact hours.

    Maintenance of Certification (MOC) Statement

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


    How to Earn/Claim MOC


    •    For each module that you wish to claim MOC points for you must:


                o    Complete the pre-test


                o    Review/watch the slides in the presentation


                o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)


                o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)


    •    AASLD submits MOC points on behalf of its learners to ABIM once a month between 15th-20th. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.


    •    MOC points are available for ABIM board certified physicians only.


    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing health-care related products and/or services. Disclosures are collected prior to the start of the educational activity any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.
    The organizers and faculty have reported the following disclosures:

    Marc Ghany, MD
    Nothing to disclose

    Tram Tran, MD
    Grant/Research Support: Bristol-Myers Squibb, Gilead; Consulting: Bristol-Myers Squibb, Gilead
    Advisory Committee or Review Panels: Bristol-Myers Squibb, Gilead

    Marion Peters, MD
    Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

    Anna S.F. Lok, MD
    Grant/Research Support: BMS and Gilead

    Brian McMahon, MD, FAASLD
    Grant/Research Support:  Gilead Sciences- grant received by department at institution and not directly.

    Maureen Jonas, MD
    FacultyAdvisory Committee or Review Panels: Served as chair of DSMB for Gilead
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Roche, Echosens (equipment only)
    Consulting: AbbVie

    Lauren Beste, MD
    Nothing to disclose

    Michael Fried, MD, FAASLD
    Organizer, Faculty
    Grant/Research Support: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and NIH
    Scientific Consultant: AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and TARGET PharmaSolutions

    Guadalupe Garcia-Tsao, MD
    Advisory Committee: Abbvie, Fibrogen

    Leslie Hayes, MD
    Nothing to disclose

    Patrick Horne, MSN, ARNP, FNP-BC
    Consulting: Gilead Sciences, Bristol-Myers-Squibb, AbbVie

    Rennie Mills, PA-C
    Advisory Board: Gilead

    Minhhuyen Nguyen, MD
    Nothing to disclose

    Norah Terrault, MD
    Organizer, Faculty
    Consulting: Dynavax Technologies, Novartis Pharmaceuticals, Echosens North America Inc
    Continuing Medical Education: Practice Point Communications, Focus Medical Communications, Med IQ, PRIME Education Inc 
    Educational Material Development: CCO Hepatitis

    John Ward, MD
    Nothing to disclose

    Stephanie Graham, MA
    AASLD Staff
    Nothing to disclose

    Claudia Ventura
    AASLD Staff
    Nothing to disclose

    Online Learning Committee

    Calvin Q. Pan, MD, MACP, FAASLD
    Advisory Board: BMS, Gilead, Abbvie Grants/Research Support:  Gilead, Merck  Speakers Bureau: BMS, Gilead, Abbvie, salix, Synergy

    Lopa Mishra, MD, FAASLD
    Nothing to Disclose

    Gene Y Im, MD
    Nothing to Disclose

    Iris W Liou, MD
    Nothing to Disclose

    Jesse M Civan, MD
    Education: Merck

    HoChong Gilles, FNP
    Nothing to Disclose

    Julius Wilder, MD, PhD
    Nothing to Disclose

    Nicolas M Intagliata, MD
    Consulting: Vital Therapies Grants/Research Support: Vital Therapies, Eisai, Sequana Medical

    Andrew S. deLemos, MD
    Consulting: Novartis

    Samar H. Ibrahim, MBCHB
    Nothing to Disclose

    This enduring material may contain discussion of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference of an unlabeled or investigational use.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • Role of Diet and Exercise in the Management of NAFLD

    Contains 1 Component(s) Recorded On: 04/24/2018

    Webinar hosted by the Non-Alcoholic Fatty Liver Disease Special interest group April 24, 2018.

    In this webinar, we will review the role of diet and exercise in the management of NAFLD. Specifically, we will overview the data in support of specific nutritional programs and physical activity regimens that have been shown to improve histologic components of NAFLD and NASH. Lastly, we will outline the remaining knowledge gaps and barriers related to lifestyle interventions in the treatment of NAFLD/NASH.

    Michelle Long

    Dr. Long is an Assistant Professor of Medicine at the Boston University School of Medicine in Boston Massachusetts and an investigator at the Framingham Heart Study. Dr. Long is hepatologist and physician scientist with a clinical specialization in non-alcoholic fatty liver disease (NAFLD). Her primary research focus is in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD. 

    Monica A. Konerman

    Dr. Monica Konerman is a Clinical Lecturer in Internal Medicine in the Division of Gastroenterology and Hepatology at the University of Michigan. She is board certified in Transplant Hepatology and conducts clinical and health services research. Her areas of interest include NAFLD/NASH, liver transplant, and clinical risk prediction.

    Rohit Loomba (Moderator)

    Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.

  • Cost-Effective Approach to Evaluation of Abnormal Liver Enzymes

    Contains 1 Component(s) Recorded On: 04/19/2018

    Webinar hosted by the Clinical Practice Special interest group April 19, 2018.

    This webinar will focus on best practices regarding evaluation of the patient presenting with abnormal liver enzymes. The focus will be not only on testing needed to arrive at the appropriate diagnosis, but also how to approach testing to minimize costs. This is an essential part of the daily practice for hepatologists and gastroenterologists.

    Vinay Sundaram (Moderator)

    Dr. Vinay Sundaram is a transplant hepatologist at Cedars-Sinai Medical Center, where he serves as assistant medical director of liver transplantation and director of hepatology outcomes research. He has been a member of the AASLD since 2009. He is actively involved with numerous committees including the AASLD membership and mentorship committee, chair of the education subcommittee for the clinical practice special interest group.  In addition, he is on the membership and professional standards committee for UNOS. His research interests include end-stage liver disease, acute on chronic liver failure and post-transplant outcomes. He has over 100 published manuscripts and abstracts and is on the editorial board for Hepatology Communications. 

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

  • Surgical Risk in the Portal Hypertensive Patient

    Product not yet rated Contains 1 Component(s) Recorded On: 03/07/2018

    Webinar hosted by the Portal Hypertension Special Interest group on March 7, 2018.

    The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.

    Brett E. Fortune (Moderator)

    Dr. Brett E. Fortune, MD, MSc, is a Transplant Hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation. His research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.

    Theo Heller (Moderator)

    Dr. Heller is a senior clinical investigator at the National Institutes of Health where he heads the Translational Hepatology Section. His research focuses on liver disease progression with a particular focus on non-cirrhotic portal hypertension as a model for all patients with portal hypertension. He is focused on enhancing the clinical care of patients with portal hypertension while elucidating mechanisms that underlie the development of portal hypertension due to any etiology. His research encompasses translational and clinical techniques with the ultimate aim of ensuring superb outcomes for patients with liver disease.


    Lawrence S. Friedman

    Dr. Lawrence S. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins School of Medicine combined BA/MD program. He did his residency training at Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital. He was on the faculty of Jefferson Medical College, where he served as Vice Chairman of the Department of Medicine and a member of the Gastrointestinal Unit at Massachusetts General Hospital. He is Professor of Medicine at Harvard Medical School and Tufts University School of Medicine. Since July 1, 2003, he has been Chair of the Department of Medicine at Newton-Wellesley Hospital and Assistant Chief of Medicine at Massachusetts General Hospital.

    Manuel I. Rodriguez-Davalos

    Dr. Manuel Rodriguez-Davalos is currently the surgical director of pediatric liver transplantation at Primary Children’s Hospital in Salt Lake City, Utah, and the medical director of the living donor liver transplantation program at Intermountain Medical Center. He was an Associate Professor of Surgery and Pediatrics at the Yale School of Medicine, where he was also the Director of Pediatric Transplantation at the Yale New Haven Transplantation since 2012. He was the liver review board primary representative for CTYN and served as Region 1 representative in the OPTN/UNOS Pediatric Transplantation Committee. He has been involved in research of ischemia reperfusion injury and the development of novel means for perfusion and preservation techniques to improve graft quality, expand the donor pool. His projects during the past 5 years in translational research involve the use of partial grafts and extended criteria for donation in liver transplantation, preservation techniques for decreasing ischemia-reperfusion injury in intestinal and liver grafts. He is collaborating with the Yale School of Engineering on the design and use of new perfusion devices for organ preservation and research.

  • Acute on Chronic Liver Failure in Children

    Contains 1 Component(s) Recorded On: 02/15/2018

    Webinar hosted by the Pediatric Liver Disorders Special Interest group on February 15, 2018.

    Acute on chronic liver failure is increasingly understood in adults, less so in children. The aims of this Webinar are to increase understanding about the causes of acute liver decompensation in children with chronic, compensated liver disease, and the acute-care management of ACLF. 

    John Bucuvalas (Moderator)

    John Bucuvalas MD, FAASLD is Professor of Pediatrics and has a broad background in transplant hepatology. He has published broadly on outcomes following liver transplantation, acute liver failure and adherence after liver transplantation.  He has  established strong ties with pediatric solid organ transplant community and with the liver transplant community thru SPLIT, NIH, AST and UNOS. 

    Simon P. Horslen

    Simon Horslen MB ChB FRCPCH FAST FAASLD is a Professor in the Division of Pediatric Gastroenterology, Hepatology & Nutrition at Seattle Children’s Hospital and the University Of Washington School Of Medicine. He is Medical Director for Solid Organ Transplantation at Seattle Children’s Hospital. He is a Pediatric Hepatologist and Transplant Physician with many years’ experience of liver and intestinal transplantation in children.  Dr Horslen participates in several multicenter research studies including SPLIT (Studies in Pediatric Liver Transplantation), PALF (Pediatric Acute Liver Failure) and ChiLDREN (Children’s Liver Disease Research Network).

    Akash Deep

    Dr. Akash Deep is the Director of the Pediatric Intensive Care Unit at King's College Hospital, London; one of the largest pediatric liver transplant centers in the world. Dr. Deep is the Chair for the Renal/CRRT Section of European Society of Pediatric and Neonatal Intensive Care Society (ESPNIC). He is the co-Chair for the Science and Education Committee of Pediatric Intensive Care Society (PICS) of UK. His special interests include acute liver failure, acute on chronic liver failure, liver assist devices in liver failure, acute kidney injury, CRRT and hemodynamics in septic shock.

  • Leon Schiff SOA: Acute on Chronic Liver Failure

    Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.  

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Patrick S. Kamath

  • 2017 Clinical Hepatology Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2017.

    This session will provide a summary of the clinical highlights from The Liver Meeting®.

    Michael W. Fried

    Kris V. Kowdley

  • 2017 NAFLD Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's NAFLD Debrief presented at The Liver Meeting® 2017.

    This newly added session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from the meeting. 

    Michael W. Fried

    Kymberly Watt

  • 2017 Hepatitis Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's Hepatitis Debrief presented at The Liver Meeting® 2017.

    This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.

    Michael W. Fried

    Paul Y. Kwo

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

  • Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science

    Product not yet rated Contains 2 Component(s) Recorded On: 10/23/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    Drug-induced liver injury (DILI) remains the leading cause of acute liver failure in the U.S. This session will review methods that are used by clinical and regulatory scientists to gather information about the hepatotoxicity of a drug or biological agent, during each phase of its life cycle.  The session will highlight the diverse clinical signatures and mechanisms that underlie DILI and discuss critical challenges when analyzing drug-related risk for serious liver toxicity.

    Robert J. Fontana

    Mark I. Avigan